{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:59:16Z","timestamp":1782334756066,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jcte.2013.12.001","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T16:48:54Z","timestamp":1390409334000},"page":"e3-e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects"],"prefix":"10.1016","volume":"1","author":[{"given":"Antonella","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Murgatroyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Dobbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"Bullmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.R.","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcte.2013.12.001_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.jcte.2013.12.001_bib2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"157","key":"10.1016\/j.jcte.2013.12.001_bib3","first-page":"47","article-title":"Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management","author":"Del Prato","year":"2007","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.jcte.2013.12.001_bib4","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter","volume":"263","author":"Wells","year":"1992","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.jcte.2013.12.001_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","article-title":"Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level","volume":"320","author":"Katsuno","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jcte.2013.12.001_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models","volume":"327","author":"Fujimori","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.jcte.2013.12.001_bib7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0091270009352185","article-title":"Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study","volume":"50","author":"Hussey","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jcte.2013.12.001_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2011.01462.x","article-title":"Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients","volume":"14","author":"Dobbins","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.jcte.2013.12.001_bib9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jcte.2013.12.001_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/oby.2007.29","article-title":"Validation of a quantitative magnetic resonance method for measuring human body composition","volume":"16","author":"Napolitano","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.jcte.2013.12.001_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/cs0820687","article-title":"Four-component model for the assessment of body composition in humans: comparison with alternative methods, and evaluation of the density and hydration of fat-free mass","volume":"82","author":"Fuller","year":"1992","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jcte.2013.12.001_bib12","series-title":"Energy and protein requirements. Report of a joint FAO\/WHO\/UNU expert consultation, Report No. 724","year":"1985"},{"issue":"2","key":"10.1016\/j.jcte.2013.12.001_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/oby.2009.272","article-title":"Finer N Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens","volume":"18","author":"Swe Myint","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jcte.2013.12.001_bib14","series-title":"Techniques for Measuring Body Composition","first-page":"223","article-title":"Body composition from fluid spaces and density: analysis of methods","author":"Siri","year":"1961"},{"issue":"3","key":"10.1016\/j.jcte.2013.12.001_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/ajcn\/35.3.591","article-title":"Validation of saliva sampling for total body water determination by H2 18O dilution","volume":"35","author":"Schoeller","year":"1982","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"10.1016\/j.jcte.2013.12.001_bib16","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1210\/jc.2006-0166","article-title":"Elevated plasma adiponectin in humans with genetically defective insulin receptors","volume":"91","author":"Semple","year":"2006","journal-title":"Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jcte.2013.12.001_bib17","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.jcte.2013.12.001_bib18","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00125-009-1508-3","article-title":"Savage\u00a0DB correlation of the leptin\/adiponectin ratio with measures of insulin resistance in non-diabetic individuals","volume":"52","author":"Finucane","year":"2009","journal-title":"Diabetologia"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623713000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623713000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:51:46Z","timestamp":1762005106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214623713000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S2214623713000033"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2013.12.001","relation":{},"ISSN":["2214-6237"],"issn-type":[{"value":"2214-6237","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}